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ABSTRACT Acquisition of numerous virulence determinants affords Staphylococcus aureus greater pathogenicity than other
skin-colonizing staphylococci in humans. Additionally, the metabolic adaptation of S. aureus to nonrespiratory conditions en-
countered during infection (e.g., hypoxia, nitric oxide, iron chelation) has been implicated as contributing to S. aureus viru-
lence. Specifically, S. aureus has been shown to ferment glycolytic substrates in nonrespiratory environments encountered
within the host. Here, we show that S. aureus has acquired unique carbohydrate transporters that facilitate the maximal uptake
of host sugars and serve to support nonrespiratory growth in inflamed tissue. The carbohydrate substrates of 11 S. aureus trans-
porters were identified, and at least four of their genes encode S. aureus glucose transporters (glcA, glcB, glcC, and glcU). More-
over, two transporter genes (glcA and glcC) are unique to S. aureus and contribute disproportionately to the nonrespiratory
growth of S. aureus on glucose. Targeted inactivation of sugar transporters reduced glucose uptake and attenuated S. aureus in a
murine model of skin and soft tissue infections. These data expand the evidence for metabolic adaptation of S. aureus to invasive
infection and demonstrate the specific requirement for the fermentation of glucose over all other available carbohydrates. Ulti-
mately, acquisition of foreign genes allows S. aureus to adopt a metabolic strategy resembling that of infiltrating host immune
cells: high glycolytic flux coupled to lactate excretion.
IMPORTANCE The bacterial pathogen Staphylococcus aureus causes a wide range of human infections that are costly and diffi-
cult to treat. S. aureus differs from closely related commensal staphylococci in its ability to flourish following the invasion of
deeper tissue from the skin surface. There, S. aureus primarily uses glucose to grow under respiration-limiting conditions im-
posed by the immune system. It was previously unclear how S. aureus thrives in this environment when other Staphylococcus
species cannot. Our results provide evidence that S. aureus has acquired an expanded repertoire of carbohydrate transporters. In
particular, four glucose transporters contribute to efficient S. aureus growth during infection. Thus, S. aureus has evolved to
maximize its glucose uptake abilities for enhanced glycolytic flux during tissue invasion. This dependence on glucose acquisition
for S. aureus virulence may also explain links between serious infectious complications associated with diabetic patients exhibit-
ing elevated blood glucose levels.
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Staphylococcus aureus is a Gram-positive coccus that asymp-tomatically colonizes healthy human skin (1, 2). However, a
compromised skin barrier or mucous membrane can lead to se-
vere S. aureus infections, including: skin and soft tissue infections
(SSTIs), bacteremia, osteomyelitis, pneumonia, and toxic shock
syndrome (3–5). Many other species of staphylococci (e.g., S. epi-
dermidis, S. haemolyticus, S. saprophyticus, etc.) also colonize hu-
man skin but cause disease far less frequently and with less severity
than S. aureus (6). This difference has been extensively studied and
is generally attributed to the combined presence of numerous
unique virulence factors in the S. aureus genome, such as toxins,
adhesins, antiphagocytic factors, and protein A (7–9). Absent
from this explanation is the contribution of metabolic adaptation.
The S. aureus life cycle can plausibly be described as low-level
growth on the skin surface with periodic penetration of deeper
tissue environments marking a phase of enhanced growth and
increased incidence of transmission. Major physiological differ-
ences between the skin surface and underlying tissue include ox-
ygen concentrations, micronutrient availability, nitrogen sources,
carbon sources, and pH (10–12). In general, the skin surface has
lower levels of carbohydrates and peptides, relatively high levels of
oxygen, and an acidic pH. Sterile tissue, on the other hand, con-
tains an abundance of carbohydrates and peptides, lower levels of
free oxygen, and a more neutral pH. However, invasion of sterile
tissue by S. aureus leads to the activation of several innate immune
responses that combine to limit bacterial respiration (e.g., iron
chelation, nitric oxide [NO] production, and robust oxygen con-
sumption by innate immune cells) (13–17). Thus, natural selec-
tion would dictate that S. aureus has adapted to take advantage of
the unique metabolites present within sterile tissue (e.g., peptides
and carbohydrates) in a manner compatible with increased resis-
tance to host inflammation (i.e., respiration inhibition).
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Recently, we demonstrated that S. aureus requires both glyco-
lysis and lactate fermentation for SSTIs and bloodstream infec-
tions and that only carbohydrates support the growth of S. aureus
under both high NO stress and anaerobiosis (i.e., nonrespiratory
conditions) (13, 16). Additionally, the lack of abundant iron
during infection limits respiration and necessitates high glyco-
lytic flux coupled to lactate excretion (15, 17). This metabolic
strategy, which is similar to that of activated immune cells, allows
for the generation of ATP in a redox-balanced, respiration-
independent manner. However, aside from the presence of a
unique lactate dehydrogenase gene (ldh1) in the S. aureus ge-
nome that promotes enhanced redox balancing during respi-
ration inhibition, there is a lack of molecular evidence support-
ing a contribution of metabolic adaptation to infection as a
distinguishing characteristic of S. aureus (13). Given the high
evolutionary conservation of glycolysis among the kingdoms of
life, we postulated that metabolic adaptation to promote high
glycolytic flux would most easily be achieved by the acquisition
of additional carbohydrate importers (18).
Bacterial carbohydrate transporters can be divided into those
that modify the sugar during transport (i.e., phosphotransferase
system [PTS] transporters) and those that do not (i.e., primary
and secondary active transporters) (19–21). PTS transport pro-
ceeds via a phosphorelay system that transfers the phosphoryl
group of phosphoenolpyruvate (PEP) through a series of carrier
proteins (EI and HPr) to a transporter (EII) and then on to the
sugar as it is imported. PTS sugar transporters are composed of at
least three subunits: EIIA, EIIB, and EIIC. The EIIA and EIIB
subunits transfer the phosphoryl group from HPr to the sugar,
while the EIIC subunit acts as a sugar-specific transmembrane
receptor. Interestingly, the EII subunits may be encoded as indi-
vidual polypeptides or fused into multisubunit proteins. PTS-
dependent carbohydrate transport is unique to bacteria and is the
predominant form of sugar uptake. PTS-dependent transport is
also functionally linked to the transcriptional regulation of cellu-
lar metabolism via carbon catabolite repression (mediated by
CcpA in Gram-positive bacteria), which further contributes to
overall metabolic efficiency.
In this report, we show that S. aureus exhibits better nonrespi-
ratory growth than other skin-dwelling staphylococci and par-
tially attribute this phenomenon to an increased capacity for car-
bohydrate import. More specifically, we identify the carbohydrate
substrates for 11 putative sugar transporters and demonstrate that
S. aureus exhibits preferential uptake of glucose during infection
as a result of the combined activities of at least four glucose trans-
porters, two of which are newly acquired and therefore unique to
S. aureus.
RESULTS
S. aureus exhibits better anaerobic growth than other staphylo-
cocci. S. aureus grows in the presence of NO levels that inhibit
both respiration and the growth of other staphylococci (13). To
test whether this enhanced growth behavior occurs under other
nonrespiratory conditions, we compared the anaerobic growth of
S. aureus strains COL and LAC to that of S. epidermidis RP62A,
S. haemolyticusATCC 29970, and S. saprophyticusATCC 15305 in
a rich medium. Both strains of S. aureus exhibited better growth
than the other Staphylococcus species, as evidenced by significantly
greater growth rates and terminal optical densities (ODs) (Fig. 1A
and B). Next, we compared the anaerobic growth of S. aureusCOL
to that of the other staphylococcal species in chemically defined
medium (CDM) with glucose as the primary carbon source. Once
again, S. aureus exhibited better anaerobic growth than the other
Staphylococcus species (Fig. 1C and D). These data suggest that
unique glycolytic and/or fermentative capabilities account for the
enhanced growth of S. aureus under nonrespiratory conditions.
S. aureus encodes an expanded repertoire of predicted car-
bohydrate transporters. One explanation for the increased
growth rate of S. aureus under nonrespiratory conditions could be
an increased capacity to import fermentable carbohydrates. To
test this hypothesis, we performed a comparative genome analysis
of putative carbohydrate transporters encoded by S. aureus COL,
S. aureus LAC, S. epidermidis RP62A, S. haemolyticus JCSC1435,
and S. saprophyticus ATCC 15305. We found that S. aureus en-
codes the largest total number of carbohydrate transporters (22),
as well as the most unique carbohydrate transporters (10) (Fig. 2;
see Table S1 in the supplemental material). Interestingly, 4 of the
10 unique S. aureus alleles are predicted to encode glucose trans-
porters: SAUSA300_0191 (glcA), SAUSA300_0194, SAUSA300_
0236 (glcC), and SAUSA300_0259 (see Table S1). Importantly,
glucose is (i) largely absent from the skin surface, (ii) the most
abundant free carbohydrate in human serum, and (iii) used by
activated innate immune cells to both produce and resist inflam-
matory radicals.
Carbohydrate uptake in S. aureus is mostly PTS dependent
and contributes disproportionately to nonrespiratory growth.
The majority (21/29) of putative S. aureus carbohydrate transport
proteins are predicted to be PTS proteins. Thus, we decided to test
the contribution of PTS-dependent carbohydrate transport to the
nonrespiratory growth of S. aureus by using a PTS-deficient stain
of S. aureus (ptsH-H15A). The H15A substitution in PtsH pre-
vents the transfer of the phosphoryl group from EI to PtsH,
thereby inhibiting PTS-dependent sugar uptake but not directly
affecting interactions with CcpA, the master regulator of carbon
catabolite repression (21). To confirm the efficacy of this muta-
tion and identify PTS-dependent substrates, we compared the aer-
obic growth of wild-type (WT) and ptsH-H15A mutant S. aureus
on 16 different carbohydrates. Previous studies demonstrated
PTS-dependent utilization of at least seven carbohydrates (lac-
tose, fructose, galactose, maltose, sucrose, glucose, and mannitol)
by S. aureus (23). In line with these observations, we found that
loss of PTS-dependent sugar uptake prevented S. aureus growth
on 10 carbohydrates (mannose, fructose, galactose, mannitol,
N-acetylglucosamine, N-acetylmannosamine, maltose, sucrose,
trehalose, lactose, and turanose) and reduced its growth on two
carbohydrates (glucose and maltotriose) but did not affect its
growth on ribose (Table 1). These data show that S. aureus carbo-
hydrate utilization is largely PTS dependent.
Nonrespiratory fermentation of carbohydrates is inherently
less energy efficient than respiration. Consequently, S. aureus
must consume three times the amount of glucose under fermen-
tative growth as under respiratory conditions in order to produce
equivalent biomass (dry weight) (Fig. 3A). Maintaining this ele-
vated level of sugar catabolism necessitates more efficient uptake
of carbohydrates, particularly under nonrespiratory conditions.
Accordingly, despite the large reduction in carbohydrate utiliza-
tion in the PTS-deficient strain, aerobic growth of S. aureus LAC
in complex medium is largely unaffected (Fig. 3B). In contrast, the
PTS-deficient mutant exhibited a significant reduction in growth
under anaerobic conditions (Fig. 3C), under NO stress (Fig. 3D),
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and under metal-limited conditions (Fig. 3E). Similar results were
obtained with S. aureus COL (data not shown). Thus, the in-
creased reliance of S. aureus on carbohydrate transport during
nonrespiratory growth implicates carbohydrate transporter ac-
quisition as a possible mechanism of metabolic adaption of S. au-
reus to infection.
Substrate identification for individual S. aureus PTS pro-
teins. To identify the sugar specificity of individual S. aureus PTS
FIG 1 S. aureus displays better anaerobic growth than CoNS. Anaerobic growth of S. aureus (SA) COL and LAC, S. epidermidis (SE) RP62A, S. haemolyticus (SH)
ATCC 29970, and S. saprophyticus (SS) ATCC 15305 in TSB (A) and CDM plus 25 mM glucose (C) (n 3). Corresponding average growth rates for TSB and
CDM plus glucose are displayed in panels B and D, respectively (n 3; error bars show the pooled standard error of the mean). Growth rates were calculated from
2 to 4 h (S. aureus LAC) and 3 to 5 h (S. aureus COL, S. epidermidis, S. haemolyticus, and S. saprophyticus) in TSB and from 2 to 8 h in CDM plus 25 mM glucose.
Statistical significance was calculated with a Student two-sided t test (***, P 0.001). Abs, absorbance.
FIG 2 S. aureus Encodes enhanced carbohydrate transport capability. Shown is a Venn diagram depicting the presence and conservation of putative carbohy-
drate transport proteins in the genomes of S. aureus COL, S. epidermidis RP62A, S. haemolyticus JCSC1435, and S. saprophyticus ATCC 15305. S. aureus encodes
more overall transporters (n 22) and the highest number of unique transporters not found in any of the other species (n 10).
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proteins, we screened mutants with insertions in all of the pre-
dicted PTS protein-encoding genes for aerobic growth defects on
selected carbohydrates. Previous studies identified fruA and
mtlFA as encoding fructose and mannitol importers, respectively
(24, 25). In support of these observations, we found that the mtlF
and mtlA mutants were unable to grow on mannitol, while S. au-
reus COL, a natural fruA mutant, exhibited poorer growth than
S. aureus JE2 on fructose. Additionally, we identified PTS trans-
port proteins contributing to the uptake of nine other carbohy-
drates. Overall, our results link individual PTS transport proteins
to the uptake of 11 of the 12 PTS-dependent sugars (Table 2). All
phenotypes were confirmed in a second S. aureus strain (COL)
background following transduction (data not shown). Consistent
with the growth phenotypes of the ptsH-deficient mutant, not a
single S. aureus PTS transposon mutant displayed a growth defect
on glucose, suggesting that glucose uptake (i) is genetically redun-
dant and (ii) likely requires both PTS and non-PTS-dependent
transporters.
S. aureus glucose transport is highly redundant. To identify
the S. aureus glucose transporters, four different candidate genes
were mutated via allelic replacement (three PTS transporters
[glcA, glcB, and SAUSA300_0236] and one non-PTS transporter
[glcU]) and then combined into all possible double, triple, and
quadruple mutants. The deleted genes were chosen on the basis of
a combination of sequence similarity to known glucose transport-
ers and high expression levels during aerobic growth on glucose
(data not shown). We found that only the S. aureus quadruple
mutant (glcA glcB glcU SAUSA300_0236) exhibited a sub-
stantial aerobic growth defect on glucose (the quadruple mutant is
referred to here as S. aureusG4, and the SAUSA300_0236 gene is
referred to as glcC) (Fig. 4A). Additionally, each putative glucose
transporter was able to independently complement the aerobic
growth defect of the S. aureus G4 mutant on glucose (Fig. 4B).
Lastly, we found that attenuation ofG4 mutant growth was fairly
specific to glucose (see Table S2 in the supplemental material)
(ManNAc and GlcNAc were not tested, as GlcA and GlcC were
previously implicated in their transport; see Table S1 in the sup-
plemental material).
To confirm that glcA, glcB, glcC, and glcU encode glucose trans-
porters, we performed radiolabeled-glucose uptake assays with
WT S. aureus, the G4 mutant, and the G4 mutant containing
plasmids constitutively expressing each of the four glucose trans-
porters. The G4 mutant exhibited significantly less glucose up-
take than WT S. aureus (45% of the WT level) (Fig. 4C). Comple-
mentation of the G4 mutant with glcA, glcB, glcC, or glcU
increased its glucose uptake to 98, 110, 105, or 56% of the WT
level, respectively. The lack of significant uptake complementa-
tion by glcU could be explained by the fact that glcU encodes a
member of the glucose/ribose porter family, a family of secondary
active transporters that rely on proton motive force (PMF) for
energy (26, 27). The dense cell pellet conditions required to per-
form these uptake assays likely have a negative impact on PMF.
This would specifically decrease the activity of PMF-dependent
GlcU more than that of the PEP-dependent PTS transporters
GlcA, GlcB, and GlcC. Importantly, the S. aureus G4 mutant is
still capable of importing glucose and exhibits residual aerobic
growth on glucose. These data indicate the presence of an addi-
tional glucose transporter(s).
To rule out the contribution of other PTS-dependent trans-
porters to S. aureus glucose uptake, we compared the aerobic
growth of WT and G4, ptsH-H15A glcU, and ptsH-H15A glk
mutant S. aureus COL. Glucose kinase, encoded by glk, is respon-
sible for phosphorylating intracellular glucose taken up by non-
PTS transporters. Thus, without glk, intracellular glucose cannot
be catabolized unless transported via PTS proteins. The growth of
the S. aureus G4 and ptsH-H15A glcU mutants was indistin-
guishable, whereas the S. aureus ptsH-H15A glk mutant exhib-
ited no residual growth in CDM with glucose as the primary car-
bon source (see Fig. S1 in the supplemental material). These data
indicate that one or several unidentified non-PTS-dependent
transporters are responsible for the remaining S. aureus G4 glu-
cose uptake observed.
GlcA and GlcC contribute disproportionately to the non-
respiratory growth of S. aureus on glucose. Next, we compared
the aerobic, anaerobic, and NO-exposed growth of the various
S. aureus glucose transporter mutants in CDM with glucose as the
primary carbon source. The two triple mutants lacking both
unique glucose transporters (GlcA and GlcC), and thus only ex-
pressing GlcB or GlcU, grew significantly more poorly than the
other triple mutants, in which either GlcA or GlcC remained func-
tional (Fig. 4D and E). This suggests that the unique glucose trans-
porters GlcA and GlcC contribute disproportionately to S. aureus
growth on glucose under nonrespiratory conditions. The ability of
either GlcA or GlcC alone to individually maintain WT growth
under nonrespiratory conditions cannot be explained by its ex-
pression level. The glcA transcript levels were commensurate with
those of glcB and glcU (see Fig. S2 in the supplemental material).
Moreover, glcC transcription was less robust under all of the con-
ditions tested. Furthermore, none of the glucose transporter genes
responded to the presence or absence of glucose or to respiratory
inhibition, with the exception of glcC, which showed modest in-
duction under anaerobiosis. Thus, other factors must explain the
ability of GlcA or GlcC to fully restore growth by itself, such as
translation efficiency, protein stability, and/or affinity for glucose.
TABLE 1 Identification of PTS-dependent carbohydrates that support
growth of S. aureus
Sugar
Growth of:
COL LAC
WT ptsH-H15A mutant WT ptsH-H15A mutant
Glucose a   
Mannose  
Fructose  
Galactose  
Ascorbate
Mannitol  
Sorbitol
GlcNAc  
ManNAc  
Ribose    
Maltose  
Sucrose  
Trehalose  
Lactose  
Turanose  
Maltotriose    
a, grows as well as when cultured with glucose; , grows to same terminal
OD as when cultured on glucose, but delayed 10 h; , does not grow to maximal
terminal OD.
Vitko et al.
4 ® mbio.asm.org May/June 2016 Volume 7 Issue 3 e00296-16
Richmedium provides alternative carbohydrates to support
nonrespiratory growth of S. aureus. We hypothesized that the
acquisition of additional glucose transporters might partially ex-
plain the enhanced nonrespiratory growth phenotypes exhibited
by S. aureus in both CDM and rich medium. Thus, we compared
the growth of WT S. aureus (normal transport) with that of the
G4 (significantly reduced glucose uptake) and ptsH-H15AglcU
(severe defect in all carbohydrate import) S. aureus (COL and
LAC) mutants in Bacto tryptic soy broth (TSB; BD; catalog no.
211825) under respiratory and nonrespiratory conditions. We ob-
served almost no growth defect in the S. aureus G4 mutants
under aerobic or nonrespiratory conditions in TSB (including NO
stress, anaerobiosis, and metal chelation) (see Fig. S3 in the sup-
plemental material). This suggests that glucose transport is non-
essential for growth under nutrient-rich conditions, perhaps be-
cause of the presence or uptake of other carbohydrates. In line
with this hypothesis, we observed an additive effect of the glcU
and ptsH-H15A mutations under aerobic conditions (see Fig. S3).
However, the ptsH-H15A glcU mutant exhibited drastic growth
rate reductions under nonrespiratory conditions, including an-
aerobiosis, NO·exposure, and metal chelation (see Fig. S3). These
data indicate that carbon is not a limiting factor for S. aureus in
TSB and that uptake of other carbohydrates can compensate for a
reduction in S. aureus glucose uptake even when high glycolytic
flux is required upon respiration inhibition.
Glucose uptake contributes to S. aureus virulence in a mu-
rine SSTI model. To investigate the relative contributions of glu-
cose and other carbohydrates to S. aureus growth or survival dur-
ing infection, C57BL/6 mice were subcutaneously infected with 1
 107 CFU of WT or G4, ptsH-H15A, ptsH-H15A glcU, or
glcUmutant S. aureus LAC. At 5 days postinfection, the S. aureus
G4 mutant was significantly attenuated by the abscess burden
FIG 3 PTS-dependent carbohydrate uptake contributes disproportionately to the nonrespiratory growth of S. aureus. (A) Glucose yield (milligrams of glucose
consumed per milligram [dry weight] of biomass) of S. aureus COL under respiratory and nonrespiratory (anaerobic and NO-stressed) conditions (n 3; error
bars show the standard error of the mean). S. aureus consumes ~3-fold more glucose per cell under nonrespiratory conditions. Statistical significance was
calculated with a Student two-sided t test (*, P 0.01). (B to E) Growth curves of WT and PTS-deficient (ptsH-H15A) S. aureus LAC in TSB under aerobic (B),
anaerobic (C), NO-stressed (D), and metal-limiting (E) conditions (n 3). Abs, absorbance.
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(~1 log), while the ptsH-H15A mutant, despite losing the func-
tions of three of the four glucose transporters and all other PTS
carbohydrate transporters, was not significantly attenuated
(Fig. 5A). Combining the glcU and ptsH-H15A mutations re-
sulted in greater attenuation than S. aureus G4 alone (~2-log
difference from the WT). This difference was not just due to mu-
tation of the glcU allele, as the glcU single mutant was also not
significantly attenuated in comparison with the WT. Importantly,
we observed no reversion of the ptsH-H15A mutation over the
course of infection.
Interestingly, when we infected mice with a dose (1 108 CFU)
that results in measurable skin lesions, the S. aureus G4 mutant
produced almost no abscess formation, unlike the WT (Fig. 5B).
However, when grown on blood agar plates, the S. aureus G4
mutant exhibited no obvious hemolysis defects (see Fig. S4 in the
supplemental material). Altogether, these data suggest that glu-
cose is the primary carbohydrate utilized by S. aureus during skin
infections and that other carbohydrates contribute minimally to
the growth or survival of S. aureus. This conclusion is supported
by our observation that the elimination of all PTS carbohydrate
transport only attenuates S. aureus when glucose transport is also
limited (Fig. 5A). Factors that necessitate the fermentation of glu-
cose during infection include iron chelation and NO production
(13, 15, 16). Additionally, as the abscess progresses, oxygen be-
comes scarce, further limiting the efficiency of respiration. This
becomes apparent with Hypoxyprobe staining as early as day 7 but
is overwhelmingly measurable by day 12 (Fig. 5C). Thus, the com-
bination of iron chelation, NO production, and hypoxia within
S. aureus skin abscesses necessitates fermentative metabolism and
the robust import of glucose by the bacterium.
DISCUSSION
Many variables within host tissue necessitate nonrespiratory
growth, including the production of immune radicals, the seques-
tration of iron, and the inevitable hypoxia that arises at sites of
inflammation because of the rapid consumption of oxygen by
active immune cells. S. aureus has evolved to thrive under all of
these stresses provided it has a rich source of carbohydrates, par-
ticularly glucose. Under aerobic conditions, respiration contrib-
utes directly to PMF, which in turn is used to generate ATP. In the
absence of respiration, the only source of ATP is substrate level
phosphorylation. Moreover, PMF has to be adequately main-
tained by consumption of ATP and reversal of the F1F0-ATPase.
Therefore, under nonrespiratory conditions, S. aureus requires
enhanced glycolytic flux, as demonstrated by a3-fold increase in
glucose consumption (Fig. 3A).
In order to accommodate an elevated level of glycolytic flux,
S. aureus must efficiently acquire host carbohydrates. Impor-
tantly, glucose is the most abundant free carbohydrate in the hu-
man body, and elevated host glucose levels are associated with
greater S. aureus disease (11, 22, 28–30). However, efficient glu-
cose uptake is likely difficult in inflamed tissue spaces, given that
infiltrating phagocytes rapidly consume tissue glucose by running
a metabolic scheme not unlike Warburg metabolism (i.e., robust
glucose oxidation combined with extensive lactate secretion) (31).
Infiltrating neutrophils rely very little on the trichloroacetic acid
(TCA) cycle or mitochondrial respiration, likely because these
energy-efficient pathways are susceptible to the reactive immune
radicals produced by these immune cells. By acquiring additional
glucose uptake capabilities, as well as a highly active lactate dehy-
drogenase, S. aureus has distinguished itself from other skin-
dwelling staphylococci and evolved to “mimic” the metabolic
state of the host at sites of inflammation.
It should be noted that glucose is not the only substrate for the
S. aureus-specific GlcA and GlcC transporters. We found that
GlcA and GlcC are solely responsible for the uptake of GlcNAc and
ManNAc, respectively, which may be indicative of a role in pepti-
doglycan homeostasis. However, the selective pressure for these
TABLE 2 Individual PTS Tn insertions tested for growth on a subset of utilizable carbon sources
SAUSA300
Tn
insertion
locus
Gene
name
EII
subunit(s) Family
Phenotype on:
Glucose Mannose Fructose Galactose Mannitol GlcNAc ManNAc Maltose Sucrose Trehalose Lactose Maltotriose
None
0191 ptsG/glcA ABC PTS-Glc PLa CLa
0194 BC PTS-Glc
0236 BC PTS-Glc CLa
0239 A PTS-Gat
0240 B PTS-Gat
0241 C PTS-Gat
0259 A PTS-Glc
0332 C PTS-Asc
0448 BC PTS-Glc CLa PLa
1315 ABC PTS-Fru PLa
1672 BC PTS-Glc
2105 mtlA BC PTS-Fru CLa
2107 mtlF A PTS-Fru CLa
2150 lacE BC PTS-Lac CLa CLa
2151 lacF A PTS-Lac CL CL
2270 BC PTS-Glc PLa PLa
2324 BC PTS-Glc PLa
2476 glcB ABC PTS-Glc
2576 ABC PTS-Fru PL
a Phenotype confirmed with an S. aureus COL transductant: CL, complete loss of growth; PL, partial loss of growth.
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transporters during infection is likely their affinity for glucose.
This conclusion is drawn from the fact that the glcA glcC mu-
tant, which is completely devoid of GlcNAc or ManNAc import, is
fully virulent (data not shown). Thus, a role in cell wall homeo-
stasis cannot explain the maintenance of these two genes. Rather,
attenuation in the animal model of skin infection requires loss of
either all carbohydrate transport (ptsH-H15A glcU) or specific
loss of glucose transport (G4) (Fig. 5A). The fact that the ptsH-
H15A mutant alone (unable to utilize almost all carbohydrates,
with the exception of glucose) is fully virulent implies that all other
carbohydrates found within the host environment are incapable
of sustaining S. aureus in vivo.
In addition to meeting the energy needs of the cell, the effect of
glucose on S. aureus virulence factor regulation in the context of
infection should not be ignored. Specifically, in vitro glucose in-
duces the expression of S. aureus biofilm-related genes (cidA and
icaA) and modulates the expression of the genes for a master vir-
ulence regulator (agr/RNAIII), toxins (hla, sec, and tst), and pro-
tein A (spa) (32–36). This may explain the complete loss of lesion
formation in mice infected with the G4 mutant despite only a
modest reduction in the viable CFU count (Fig. 5). Although we
did not observe a loss of hemolytic activity in S. aureusG4 grown
in vitro on blood agar plates (see Fig. S4 in the supplemental ma-
terial), this experiment is not quantitative and does not rule out a
difference in the kinetics or cumulative levels of toxin production.
Similarly, we found that the S. aureus ptsH-H15A glcU mutant
exhibited normal hemolysis but displayed reduced pigment for-
mation. This defect may be explained as follows: (i) slow growth of
FIG 4 Contributions of the identified glucose transporters to the nonrespiratory growth of S. aureus. (A) Aerobic growth of WT and selected double, triple, and
quadruple S. aureus COL glucose transporter mutants in CDM plus 25 mM glucose (n 3). (B) Representative aerobic growth curve demonstrating comple-
mentation of S. aureusCOLG4 mutant growth in CDM plus 25 mM glucose by each individual glucose transporter (n 3). (C) Percent [U-14C]glucose uptake
by S. aureusCOLG4 relative to that of the WT, as well asG4 complemented with each individual glucose transporter gene. Uptake by each strain was measured
following 12 min of incubation with radiolabeled substrate and then normalized to that of the WT (n  4; error bars show the standard error of the mean).
Statistical significance was calculated with a Student two-sided t test (*, P 0.05; **, P 0.01; ***, P 0.001). (D and E) Nonrespiratory growth rate of S. aureus
COL G4, relative to that of the WT, compared to that of mutants expressing individual transporter genes from their native promoters. Strains were cultured
anaerobically (D) or under NO stress (10 mM NOC-12–1 mM DEA-NO) (E) (n  3; error bars show the pooled standard error of the mean). Statistical
significance was calculated with a Student two-sided t test (**, P 0.01; ***, P 0.001). Abs, absorbance.
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the mutant in TSB may delay sigB activation of the crtOPQMN
operon, and/or (ii) reduced carbohydrate uptake may limit the
intracellular availability of glucose, a required substrate for
staphyloxanthin production (37, 38). Regardless, our data indi-
cate that carbohydrate uptake may also contribute to S. aureus
infection via regulation of virulence factor production.
To contextualize our in vivo findings, one must also consider
that respiration, iron acquisition, and the TCA cycle have all been
shown to contribute to S. aureus virulence (39–42). Thus, we can-
not accurately state that inflamed tissue spaces are strictly non-
respiratory. However, it is clear from our work that S. aureus dis-
plays enhanced nonrespiratory growth phenotypes and that
glycolysis-based fermentation is equally required for infection.
These seemingly paradoxical findings can be reconciled by con-
sidering the temporal and spatial aspects of infection. For in-
stance, NO production and oxygen availability are temporally
regulated during S. aureus abscess development (14). Skin
abscess-inducible NO synthase activity is highest 1 to 7 days after
S. aureus injection and then wanes as the infection clears. How-
ever, over time, the abscesses become hypoxic (Fig. 5C). These
data suggest that S. aureus uses carbohydrate-based fermentative
metabolism to overcome instances of high NO exposure encoun-
tered early during infection and instances of hypoxia later in in-
fection. Moreover, bacteria within murine renal abscess have been
shown to be relatively starved of iron (43). Thus, until bacterial
numbers are reached such that efficient hemolysis releases hemo-
globin into the tissue, allowing S. aureus sufficient iron to respire,
S. aureus may rely on nonrespiratory metabolism to thrive, neces-
sitating rapid import of glucose.
Regardless of when or why S. aureus glycolytic and glucose
transporter-deficient mutants are attenuated during infection, the
fact that they exhibit any attenuation at all emphasizes the impor-
tance of glucose to S. aureus disease. In particular, this observation
may partially explain the unique susceptibility of uncontrolled
diabetics to S. aureus infections (30). Diabetes is an important risk
factor for S. aureus disease, with diabetic individuals exhibiting an
increased incidence and severity of S. aureus SSTIs, bloodstream
infections, and endocarditis (22, 28, 29, 44–46). If the susceptibil-
ity of diabetics to S. aureus infection is, in fact, augmented by the
enhanced propensity of S. aureus to acquire and ferment glucose,
then the development of novel S. aureus glycolysis inhibitors by
Kumar et al. may constitute a particularly effective treatment for
diabetics with S. aureus infections, one that both limits S. aureus
growth and reduces its destructive capacity during infection (47).
MATERIALS AND METHODS
Bacterial strains and medium. All staphylococci were cultivated in TSB
or CDM, wherein the primary carbon source could be modified (48).
Individual carbohydrates added to CDM were carbon balanced to 25 mM
glucose for all experiments, except the NO growth assay (see explanation
below). Casamino Acids were added to the CDM at 0.5%. Chloramphen-
icol was added to TSB (10 g/ml) and CDM (2.5 g/ml) during the
growth of plasmid-containing strains. All of the strains utilized in this
study are listed in Table S3 in the supplemental material. All mutant
strains, except the PTS insertion mutants, were generated via allelic re-
placement with Escherichia coli-S. aureus shuttle vectors pBT2ts, pBTK,
pBTE, and pBTS and the new vector pBTT as previously described (49).
pBTT was constructed by amplifying the tetK allele from S. aureus COL
plasmid pT181 (tet.3A and tet.3B) and then cloning it into the XmaI site of
FIG 5 S. aureus glucose transporter mutants show attenuated virulence in a murine SSTI model. (A) Abscess burdens on day 5 following the subcutaneous
injection of 1 107 CFU of S. aureus LAC (5 n 17; error bars show the standard error of the mean). Statistical significance was determined by analysis of
variance with multiple comparisons (*, P 0.05). (B) Lesion sizes following the subcutaneous injection of 1 108 CFU of S. aureus LAC (5 n 10; error bars
show the standard error of the mean). (C) Immunohistochemistry with antibodies against Hypoxyprobe adduct demonstrating the slow progression of abscess
tissue from relatively aerobic conditions at early time points toward hypoxic conditions at later time points.
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pBT2ts. The PTS insertion mutants were ordered from the Nebraska Mu-
tant Transposon Library (Network on Antimicrobial Resistance in Staph-
ylococcus aureus) and verified by PCR upon arrival (24). For the plasmids
and primers used for mutant construction, verification, and complemen-
tation, see Table S3. Importantly, all of the mutants used for virulence
studies were fully transduced, with the exception of the ptsH-H15A and
ptsH-H15AglcU mutants. Since the ptsH-H15A mutation is markerless,
we constructed and verified three independent ptsH-H15A mutants in the
LAC background. We then separately transduced theglcUmutation into
each of these three mutants and verified that each mutant grew identically
under aerobic conditions in glucose, Casamino acids, and TSB.
Growth curves. Staphylococcus cultures were grown overnight in TSB
at 37°C with shaking at 250 rpm. For aerobic, metal-restricted, and NO-
treated bacterial growth curves, overnight cultures of S. aureus were
washed twice with phosphate-buffered saline (PBS) and diluted into TSB
with or without 2,2-dipyridyl (1 mM) or into CDM with or without car-
bon to an initial OD at 600 nm (OD660) of 0.04. Diluted cultures were then
aliquoted into a 96-well plate (200 l/well) and incubated in a Tecan
Infinite M200 microplate reader set to 37°C with 1-mm orbital shaking.
Growth was monitored via absorbance at 650 nm every 15 min for 24 h.
For NO growth curves, 10 mM NOC-12 (Santa Cruz Biotechnology; cat-
alog no. 202246) and 1 mM DEA NONOate (A. G. Scientific; catalog no.
D-1013) were added to the cultures at an OD650 of 0.15. To extend the
fermentative phase of S. aureus NO-resistant growth, an additional, iden-
tical, dose of NO donors was added to each well 1.5 h later. To ensure
continued substrate availability during such prolonged NO exposure
(S. aureus utilizes carbon inefficiently during NO-induced fermentation),
we used 50 mM glucose for these experiments. For anaerobic growth
curves, the overnight cultures were washed twice with PBS and diluted
into 5 ml of prewarmed (37°C) TSB or CDM with or without carbon with
or without 50 mM potassium nitrate to an OD660 of 0.08. Cultures were
prepared in duplicate in 16- by 150-mm glass tubes containing 1-mm stir
bars. Following dilution, cultures were immediately transferred into a Coy
anaerobic chamber and grown at 37°C with stirring. Growth was moni-
tored hourly by reading absorbance at 650 nm.
Growth rate and lag analysis. Growth rates were calculated with the
formulaln(A650)time (hours). The time intervals used for growth
rate analysis are experiment specific and thus are provided in the figure
legends. Lag time was calculated as the time (hours) until cultures reached
an OD650 of 0.2.
Glucose yield calculation. Glucose yield was measured in milligrams
of glucose consumed per milligram (dry weight) of biomass for S. aureus
COL, our primary laboratory strain. Glucose consumption was moni-
tored by enzymatically (R-Biopharm) determining glucose in 200-l
cultures of CDM plus 25 mM glucose over a 4-h period following NO
exposure or during a 4-h period during aerobic or anaerobic growth at
mid-exponential phase. Dry-weight biomass was determined by vacuum
filtering 100 ml of mid-exponential-phase S. aureus COL culture (OD660
of 1) in triplicate through a 10-cm Millipore 0.45-m-pore-size filter. The
filter was then baked overnight at 65°C. Weights were averaged, and the
weights of baked sterile filters were subtracted to yield an average dry
weight of an S. aureus cell of ~2.8 1013 g. While S. aureusLAC (used for
animal experiments) exhibits similar elevated glucose consumption un-
der nonrespiratory conditions, the dry-weight biomass of this strain per
OD unit was not directly determined, but it is not expect to differ signif-
icantly from that of COL.
Bioinformatic analysis of carbohydrate transporters. First, we
searched the NCBI gene/protein and UniProt database S. aureus COL,
S. aureus LAC, S. epidermidis RP62A, S. haemolyticus JCSC1435, and
S. saprophyticus ATCC 15305 genomes with the keywords PTS, sugar
transporter, sugar permease, carbohydrate transporter, carbohydrate per-
mease, glucose, fructose, mannose, mannitol, sucrose, galactose, ascor-
bate, sorbitol,N-acetylglucosamine,N-acetylmannosamine, ribose, malt-
ose, trehalose, lactose, maltotriose, trisaccharides, disaccharides, and
monosaccharides. All of the putative carbohydrate transporters discov-
ered in this manner were then entered as queries in BLASTP searches
against all five of the genomes mentioned above.
All of the candidate sugar transporters from this expanded search were
then compiled into a list. Next, we performed forward and reciprocal
BLASTP searches for each predicted protein on this list against all Staph-
ylococcus genomes, as well as the transporter classification database
(http://www.tcdb.org). Sequence homology was determined with an E
value cutoff of 1e50. Lastly, we used the ortholog predictor provided
through xBASE (http://www.xbase.ac.uk/) and visually inspected/com-
pared the genomic context of each gene with MetaCyc (http://metacy-
c.org/). Homology, as depicted in Table S1 in the supplemental material,
required sequence homology (i.e., an E value of 1e50 and a positive
reciprocal BLASTP result), a corresponding result from the xBASE or-
tholog predictor, and a visual confirmation of shared genomic context.
Real-time qRT-PCR. S. aureus COL was grown in 50 ml of CDM plus
25 mM glucose or Casamino Acids (0.5%) in 250-ml flasks at 37°C with
shaking at 250 rpm. At an OD660 of 0.5, 25 ml of each culture was added to
an equal volume of ice-cold ethanol-acetone (1:1) and frozen at 80°C
(aerobic cultures). To assess gene expression during NO exposure, a sep-
arate set of cultures (CDM plus glucose) was treated with 5 mM DETA-
NONOate (Cayman Chemical; catalog no. 82120) for 1 h, quenched, and
then frozen. Lastly, S. aureus COL was grown in 50 ml of CDM plus
glucose in the anaerobic chamber at 37°C with stirring. At an OD660 of 0.5,
25 ml of culture was removed from the chamber in a 50-ml conical tube
devoid of oxygen, immediately quenched, and then frozen. RNA was then
harvested, and gene expression was analyzed as previously described (49).
Transcript levels of selected genes were normalized to rpoD transcript
levels, which deviated very little across our experimental conditions. For
the primers used for quantitative reverse transcriptase PCR (qRT-PCR)
analysis, see Table S3 in the supplemental material.
Radiolabeled-glucose uptake assays. S. aureus COL strains were
grown in TSB in 50-ml culture volumes to late exponential phase (OD660
of 1 to 1.2). Cells were centrifuged for 10 min at 5,000  g and then
immediately resuspended to an OD660 of 20 in warm CDM (37°C). At t0,
a mixture of glucose and [14C]glucose was added to a 1-ml aliquot of each
culture to reach final concentrations of 2 mM glucose and 100M [14C]g-
lucose. Cells were incubated in a 37°C heat block. At 12 min following
glucose addition, 150l of culture was removed and immediately diluted
into 900 l of CDM containing 20 mM unlabeled glucose. The diluted
cells were pelleted, washed once with 500 l of CDM (20 mM glucose),
and then resuspended in 150 l of CDM (20 mM glucose). The resus-
pended cells were added to a scintillation vial containing 4 ml of EcoScint
A scintillation fluid (National Diagnostics). To determine the level of
radioactivity in each sample, a Beckman LS6500 Multi-Purpose Scintilla-
tion Counter was used to measure counts per minute.
Hemolysis assays. To detect hemolysis activity, S. aureus LAC strains
(WT,G4, ptsH-H15A [isolates 1 to 3], and ptsH-H15AglcU [isolates 1
to 3]) were streaked onto blood agar (Remel; tryptic soy agar [TSA] with
sheep blood; catalog no. R01200) from freezer stocks and incubated at
37°C for 36 h. Plates were subsequently incubated at 4°C for 12 h and then
imaged with a digital microscope.
Virulence assays. For virulence assessment, 6- to 8-week-old female
C57BL/6 mice from The Jackson Laboratory (Bar Harbor, ME) were anes-
thetized with tribromoethanol (Avertin, 0.08 mg/kg; Acros Organics; cat-
alog no. 421430100) shaved (on the flank), and injected subcutaneously
(on the flank) with 1  107 CFU of WT or G4, glcU, ptsH-H15A, or
ptsH-H15A glcU mutant S. aureus LAC in 20 l of sterile PBS. Impor-
tantly, two separate isolates of the ptsH-H15A and ptsH-H15AglcUmu-
tants were used for infection of at least five mice apiece. On day 5, mice
were euthanized and the abscesses were removed, homogenized in 500l
of PBS, and dilution plated on TSA to enumerate CFU. To control for
reversion of the ptsH-H15A mutation during infection, WT (positive con-
trol) and ptsH-H15A and ptsH-H15AglcU mutant abscesses were plated
on CDM agar plus sucrose (25 mM), incubated at 37°C for 48 h, and then
inspected for colonies.
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Fluorescence immunohistochemistry. The Hypoxyprobe-1 Omni
kit (Hypoxyprobe Inc., Burlington, MA) was used for immunochemical
detection of tissue hypoxia. Briefly, mice were injected intraperitoneally
with 60 mg/kg pimonidazole HCl 30 min prior to euthanasia. Following
euthanasia, infected tissues were fixed in 10% formalin, paraffin embed-
ded, and sectioned (5m). Unstained sections were deparaffinized with a
series of xylene and ethanol washes, followed by antigen retrieval in boil-
ing 10 mM sodium citrate buffer (pH 6). Tissues were blocked with 10%
donkey serum (Jackson ImmunoResearch, West Grove, PA) and subse-
quently incubated with anti-Hypoxyprobe PAb2627AP (Hypoxyprobe
Inc.). The primary antibody was detected by incubation with a biotinyl-
ated donkey anti-rabbit antibody, followed by incubation with
streptavidin-conjugated Dylight 594 (Jackson ImmunoResearch). Tissues
were mounted with ProLong antifade gold containing 4=,6-diamidino-2-
phenylindole (Invitrogen, Grand Island, NY) and imaged on an Olympus
BX60 fluorescence microscope with iVision software v.4.0.0 (BioVision
Technologies, New Minas, Nova Scotia, Canada).
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